Elsevier

Clinica Chimica Acta

Volume 460, 1 September 2016, Pages 67-71
Clinica Chimica Acta

Increase of Serum CXCL16 Level Correlates Well to Microembolic Signals in Acute Stroke Patients with Carotid Artery Stenosis

https://doi.org/10.1016/j.cca.2016.06.026Get rights and content

Highlights

  • The increase in CXCL16 levels had a predictive value in acute ischemic stroke.

  • There were higher serum CXCL16 concentrations in MES positive compared to MES negative patients

  • Higher level CXCL16 contribute to plaque destabilization in ischemic stroke.

Abstract

Background

The majority of strokes are combined with the instability of atherosclerotic plaques. Microembolic signals (MES) have been considered as evidence of plaque destabilization. We found that increased CXCL16 correlated to atherosclerotic ischemic stroke. Thus, we explored whether CXCL16 correlates to MES.

Methods

The study recruited 104 controls and 118 patients with acute ischemic stroke that has an ipsilateral carotid artery stenosis of > 50%. The ipsilateral middle cerebral artery of patients was insonated for 60 min using Doppler device within 72 h of their clinical presentation.

Results

We found that CXCL16 was significantly increased in the stroke patients. Furthermore, there was a significant difference in CXCL16 between the MES-positive and MES-negative patients. Using CXCL16 to distinguish the controls and stroke patients, the area under the ROC curve (AUC) was 0.722; the cut-off value was 2.015 ng/ml. The sensitivity and specificity were 70.5% and 67.9%, respectively. Furthermore, if we used CXCL16 to distinguish the MES-positive and MES-negative patients, the AUC was 0.736; the cut-off value was 2.115 ng/ml. The sensitivity and specificity were 88.5% and 56.5%, respectively.

Conclusions

Higher levels CXCL16 may be a biomarker for predicting stroke incidence and might contribute to plaque destabilization.

Introduction

Stroke is a personal, familial and social disaster. In China, ischemic stroke accounts for > 80% of all strokes [1]. The majority of strokes (85–90%) result from cerebral ischemia. In most cases, extra - and intracranial vessel atherosclerotic changes are considered to be responsible for cerebral ischemia. Carotid artery atherosclerosis is a major risk factor for stroke and subsequent cognitive impairment [2]. A sudden failure of cerebral circulation is usually combined with the instability of atherosclerotic plaques. Plaque destabilization is evidenced clinically by the preoperative occurrence of ischemic symptoms and microembolic signals (MES). MES have been considered a readily measurable marker of increased stroke risk [3], [4] and can be detected by transcranial Doppler (TCD) [5].

Accumulating evidence indicates that inflammation is not only a component of atheromatous plaques, which promotes the initiation and evolution of atheroma [6], but, importantly, it also plays a crucial role in the destabilization of vulnerable plaques with consequent thrombosis and distal thromboembolism [7], [8], thus converting chronic atherosclerosis into an thrombo-embolic disorder [9]. Recently, a protein called CXCL16 was discovered. It is a member of inflammatory chemokine superfamily with putative roles in directing leukocyte migration and functioning as a scavenger receptor for oxidized low-density lipoprotein (ox-LDL) and chemotactic properties [10], [11]. A high expression of CXCL16/SR-PSOX mRNA and protein in the plaques of coronary and carotid atherosclerosis was observed, and CXCL16 has been proposed to act as a pathogenic mediator in atherosclerosis [10], [11], [12], [13].

However, the relationship between the circulating levels of soluble CXCL16 and atherosclerotic disorders remains controversial in the clinic. Both decreased and increased CXCL16 levels have been reported in patients with atherosclerotic disorders [14], [15]. Our previous research found that an elevation of serum CXCL16 level correlated well with atherosclerotic ischemic stroke [16]. However, there are no reports about the relationship between the levels of CXCL16 and microembolic signals (MES) in symptomatic carotid artery stenosis. The role of CXCL16 in the destabilization of atheromatous plaques has never been measured in vivo before. The goal of the present study was to investigate the serum levels of CXCL16 in patients with acute ischemic stroke from atherosclerosis of carotid artery to explore whether the circulating levels of CXCL16 correlates to MES and to further evaluate its potential value as a diagnostic biomarker for the destabilization of atheromatous plaques.

Section snippets

Subjects

A total number of 222 subjects were enrolled in the present study, including 104 controls and 118 consecutive patients with acute ischemic stroke (≤ 3 days) clinically localized to the carotid territory and with an ipsilateral carotid artery stenosis of > 50% by the North American Symptomatic Carotid Endarterectomy Trial criteria on carotid duplex ultrasonography [17]. The work was carried out in accordance with The code of ethics of the world medical association for experiments involving humans.

Statistical analysis of the patients' characteristics

The clinical characteristics of the patients and the controls are shown in Table 1. There were no significant differences in age, gender, active smoking and alcohol abuse between the patients and the controls (p > 0.05). Additionally, no differences were observed in the co-existence between coronary artery disease (CAD) and diabetes between the two groups (p > 0.05). However, significant differences were detected in the history of hypertension between the patients and the controls (p < 0.05). The

Discussion

Substantial studies have indicated that inflammatory processes play a critical role in several aspects of the pathophysiology and disease progression in acute ischemic stroke [20], [21]. Chemokines are important inflammatory mediators that are thought to play an important pathogenic role in atherogenesis and plaque destabilization by activating and directing leukocytes into atherosclerotic lesions [21]. CXCL16, a newly discovered chemokine of the CXC family, has several inflammatory functions,

Acknowledgments

The authors thank Dr. Guirong Sun. for the excellent technical assistance. This study was supported by a grant from the Shandong Province Natural Science Foundation (ZR2011HM087), the Qingdao Science and Technology Program (Grant No.14-2-4-97-jch) and the Qingdao Postdoctoral Application Research Funded Project.

References (31)

  • G.W. Yi et al.

    Overexpression of CXCL16 promotes a vulnerable plaque phenotype in Apolipoprotein E-Knockout Mice

    Cytokine

    (2011)
  • D. Zhao et al.

    Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project

    Stroke

    (2008)
  • K.A. Arntzen et al.

    Carotid atherosclerosis predicts lower cognitive test results: a 7-year follow-up study of 4,371 stroke-free subjects - the Tromso study

    Cerebrovasc. Dis.

    (2012)
  • I. Momjian-Mayor et al.

    Diagnosis of and treatment for symptomatic carotid stenosis: an updated review

    Acta Neurol. Scand.

    (2012)
  • Q. Hao et al.

    The significance of microembolic signals and new cerebral infarcts on the progression of neurological deficit in acute stroke patients with large artery stenosis

    Cerebrovasc. Dis.

    (2011)
  • Cited by (7)

    • LPS induces CXCL16 expression in HUVECs through the miR-146a-mediated TLR4 pathway

      2019, International Immunopharmacology
      Citation Excerpt :

      CXCL16 was shown to be present in the atherosclerotic lesions of both humans and apoE-deficient mice [5,6]. Previous clinical studies in our laboratory demonstrated that the serum levels of CXCL16 increase during atherosclerotic ischemic stroke [7] and are higher in patients who exhibit microembolic signals (MES) relative to MES-negative patients [8,9]. This finding suggests that CXCL16 is closely associated with the inflammatory response in atherosclerosis.

    • Biomarkers of cerebral microembolic signals

      2017, Clinica Chimica Acta
      Citation Excerpt :

      In addition, our previous research revealed a significant elevation of serum CXCL16 level in patients with atherosclerotic IS [30]. Recently, we further investigated the correlation between CXCL16 and MES and found a consistently significant increase in serum CXCL16 concentrations in MES + patients than in MES − patients [31]. In addition, the high level of serum CXCL16 was accompanied by the overexpression of markers of plaque destabilization, such as matrix metalloproteins (MMPs), CC motif chemokine ligand 2 (CCL2) and vascular cell adhesion molecule 1 [32].

    View all citing articles on Scopus
    1

    These authors contributed to the work equally and should be regarded as co-first authors.

    View full text